PDF, Patent Landscape Report on Atazanavir - WIPO

More documents

Recommendations

Info

EARLIEST PRIORITY COUNTRYDetermining the priority country (country of first filing) is the easiest way to get an idea ofwhere inventions were made, and typically corresponds to a company location. Globalcompanies may file in multiple countries if they have R&D facilities in each place. Most ofthe inventions in this collection were filed first in the US, and 70% of them were also filed ina PCT office (or have a priority in a PCT Office). This is partly explained because thepharmaceutical industry in general favors PCT filing. By examining the application numberof a PCT filing, the country of origin of the application can be determined, and Figure 15also shows the country of origin (receiving office) for the PCT applications.Observations include: a) relatively low participation in this technical field by Japanesecompanies, whether measured through in-country priority filings or PCT filings, and b)noticeable but not large participation by India. The numbers of families that have grants inone or more authorities are also shown, and is 29% for the US and 35% for the EPO. Thegrant of a patent implies novelty, but the grant rate statistic is affected by the age of theinvention, since young applications are not expected to grant in a time shorter than thenormal pendency period.Figure 15. Priority Country Information22
FAMILY MEMBER COUNTRIESLooking at patent applications in another way, it is easy to see that the companies file forprotection not only locally (priority country), but also in other regions where they expect torequire protection for their product, or for manufacturing of their product. The average sizeof the DWPI families in this collection is 5 members (5 countries where filings have beenmade). Figure 16 presents a count of the inventions filed in various countries or authorities,and countries with high numbers are presumably viewed as potential markets by thedevelopers, and may also be considered as potential sites for manufacturing. Regionalfilings in the European <strong>Patent</strong> Office may protect inventions in multiple European countriesnot listed here. Protection is Asia-Pacific countries is robust, as is protection in North andSouth America.Figure 16. Countries Viewed as Markets23
Page 4 and 5: ContentsSECTION 1: THE TWO OBJECTIV
Page 7 and 8: collection for nuggets of intellige
Page 9 and 10: CHEMICAL NAMINGChemical naming conv
Page 11 and 12: Figure 2: Legal Status for Novartis
Page 13 and 14: name, but after the patent protecti
Page 15 and 16: STAGE TWO CLINICAL SEARCHTo be more
Page 17 and 18: CLINICAL COLLECTIONThis is an examp
Page 19 and 20: THE FOUNDER PATENT AND ITS DOWNSTRE
Page 21 and 22: CHEMICAL COLLECTIONThis is an examp
Page 23: SECTION 5: GENERAL OVERVIEW OF THE
Page 27 and 28: The crossover between categories is
Page 29 and 30: THE DEVELOPER’S OWN TIMELINEThe A
Page 31 and 32: Several of the representative paten
Page 33 and 34: Figure 25. Emphasis Matrix for Sele
Page 35 and 36: PATENT QUALITY INDICATORS FOR SELEC
Page 37 and 38: Figure 30. References made by the F
Page 39 and 40: FORMULATIONSEven before a drug is a
Page 41 and 42: Figure 34. References to Bristol My
Page 43 and 44: PROPRIETARY DRUGS AND LITIGATIONThe
Page 45 and 46: TWO DRUGS DIRECTED AT THE SAME TARG
Page 47 and 48: Citations to this document mainly c
Page 49 and 50: USING OVERLAP TO FIND COMBINATIONS
Page 51 and 52: INTERNATIONAL PATENT CLASSIFICATION
Page 53 and 54: ased on the IPC, but with sometimes
Page 55 and 56: DERWENT MANUAL CODESDWPI Manual Cod
Page 58: For more information contact WIPO a

PDF, Patent Landscape Report on Atazanavir - WIPO

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?